Liraglutide

What is Liraglutide?#

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a 31-amino-acid synthetic peptide analog of human GLP-1(7-37) with two key modifications: an arginine substitution for lysine at position 34, and a C16 fatty acid (palmitic acid) chain conjugated at lysine-26 via a glutamic acid spacer, enabling non-covalent albumin binding and a half-life of approximately 13 hours.

Liraglutide is marketed under two brand names:

• Victoza (injectable): FDA-approved January 2010 for type 2 diabetes mellitus, available in 0.6 mg, 1.2 mg, and 1.8 mg daily doses
• Saxenda (injectable): FDA-approved December 2014 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, at the 3.0 mg daily dose. Expanded to adolescents aged 12-17 in December 2020.

Liraglutide holds historical significance as the first once-daily GLP-1 receptor agonist, and Saxenda was the second GLP-1 agonist approved specifically for obesity treatment (after high-dose liraglutide clinical data supported the indication). In 2025, generic liraglutide became the first generic GLP-1 receptor agonist approved for weight loss in the United States.

Mechanism of Action#

Liraglutide mimics the effects of endogenous GLP-1, an incretin hormone released from intestinal L-cells after food intake. By selectively activating the GLP-1 receptor, liraglutide produces multiple coordinated metabolic effects.

Incretin Signaling#

• Glucose-dependent insulin secretion: Stimulates pancreatic beta-cells to release insulin only when blood glucose is elevated, reducing hypoglycemia risk compared to insulin or sulfonylureas
• Glucagon suppression: Inhibits inappropriate glucagon secretion from alpha-cells in the hyperglycemic state, reducing hepatic glucose output
• Gastric emptying delay: Slows the rate at which food passes from the stomach into the small intestine, reducing postprandial glucose excursions and contributing to satiety
• Central appetite regulation: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger, increase satiety, and modify food preferences

Pharmacokinetics#

The C16 fatty acid (palmitic acid) modification at Lys26 is the key structural feature enabling once-daily dosing. This acyl chain binds non-covalently to serum albumin, creating a circulating reservoir that shields the peptide from renal filtration and enzymatic degradation. The resulting half-life of approximately 13 hours allows for once-daily subcutaneous injection. Steady-state concentrations are achieved after approximately 3-5 days of daily dosing.

Research Overview#

Liraglutide has an extensive clinical evidence base spanning multiple indications. The LEADER cardiovascular outcomes trial (9,340 patients, median 3.8 years follow-up) demonstrated a 13% reduction in MACE in patients with type 2 diabetes at high cardiovascular risk. The SCALE clinical trial program established liraglutide 3.0 mg as an effective anti-obesity therapy, with 8.0% mean body weight reduction in the pivotal SCALE Obesity and Prediabetes trial.

As the predecessor to semaglutide, liraglutide established many of the clinical paradigms now used across the GLP-1 agonist class, including dose escalation schedules and cardiovascular outcomes trial design.

Important Considerations#

• Prescription medication requiring medical supervision
• Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
• Most common adverse events are gastrointestinal (nausea, vomiting, diarrhea)
• Dose escalation schedule important to minimize GI side effects
• Should not be used with other GLP-1 receptor agonists (including semaglutide)
• Discontinue if pancreatitis is suspected

Key Research Findings#

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER), published in New England Journal of Medicine (Marso SP et al., 2016; PMID: 27295427):

• The study showed MACE reduction of 13% (HR 0.87, 95% CI 0.78-0.97, P=0.01 for superiority)
• The study showed cardiovascular death reduced by 22%
• The study showed all cause mortality reduced by 15%
• LEADER was a cardiovascular outcomes trial evaluating liraglutide in 9,340 patients with T2D and high cardiovascular risk. Liraglutide significantly reduced MACE by 13% compared to placebo over a median follow up of 3.8 years.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes), published in New England Journal of Medicine (Pi-Sunyer X et al., 2015; PMID: 26132939):

• The study demonstrated mean weight loss of 8.0% vs 2.6% at 56 weeks

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial, published in JAMA (Davies MJ et al., 2015; PMID: 26284720):

• The study showed weight loss of 6.0% , 4.7% , vs 2.0% at 56 weeks
• The study showed HbA1c reduced by 1.3% and 1.1% vs 0.3%
• The study demonstrated more patients achieved HbA1c below of 7% with liraglutide

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity (SCALE Teens), published in New England Journal of Medicine (Kelly AS et al., 2020; PMID: 32233338):

• The study showed BMI reduction of 4.64 percentage points greater with liraglutide

Related Reading#

• Liraglutide research studies and evidence
• Liraglutide dosing protocols
• Liraglutide side effects profile
• Albiglutide (Tanzeum) research guide
• Exenatide research guide